I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Diabetic Foot
Overview
The diabetic foot refers to the spectrum of lower-extremity complications arising in patients with diabetes mellitus, including ulceration, infection, neuropathic arthropathy (Charcot foot), and gangrene potentially leading to amputation. It is one of the most common and costly complications of diabetes, responsible for approximately 20% of all diabetes-related hospitalizations. A diabetic patient carries a 15% lifetime risk of developing a foot ulcer, with an annual incidence of 2%. Up to 85% of all lower extremity amputations (LEA) in diabetics are preceded by a foot ulcer, and 15-20% of ulcers ultimately result in LEA. - Campbell's Operative Orthopaedics 15th Ed 2026
Pathophysiology - The Triad
Three interacting mechanisms drive diabetic foot disease:
1. Peripheral Neuropathy
- Multifactorial: both vascular and metabolic roots
- Hyperglycemia causes glycosylation of hemoglobin and proteins, forming advanced glycation end products (AGEs) that precipitate in small vessel walls and nerve tissue
- Results in thickening of basement membranes, reduced endothelial nitric oxide activity, and epineural vessel atherosclerosis
- Metabolic causes: sorbitol accumulation, enzyme deficiencies, increased oxygen-free radical activity
- Consequences:
- Sensory neuropathy: loss of protective sensation (LOPS) - the pivotal defect; patient is unaware of injury
- Motor neuropathy: intrinsic muscle weakness, overpowered by extrinsic muscles → hammer toes, claw toes, distal migration of the fat pad, gastrosoleus contracture increasing forefoot pressure
- Autonomic neuropathy: absent skin oils → skin fissuring; decreased sweating → dry, cracked skin
- Inability to feel a Semmes-Weinstein 5.07 monofilament (10 g pressure) is the most predictive risk factor for foot morbidity
- Campbell's Operative Orthopaedics 15th Ed 2026
2. Peripheral Arterial Disease (Ischemia)
- Diabetic patients are twice as likely to develop peripheral arterial disease and 9 times more likely to develop a foot ulcer when PAD coexists
- Macro- and microvascular insufficiency combine: thickened basement membranes, medial calcinosis (arterial calcification), endothelial dysfunction
- Characteristically affects tibial and peroneal vessels (infrapopliteal)
- ABI is a useful screening tool: normal 0.9-1.2; values >1.3 suggest non-compressible calcified vessels; ABI <0.5 predicts poor healing without vascular intervention
- Absolute toe pressures >70 mm Hg needed for healing; toe-brachial index (TBI) more reliable than ABI when vessels are calcified
- Campbell's Operative Orthopaedics 15th Ed 2026
3. Infection
- Infection begins with bacterial invasion of compromised tissues and rapidly spreads to deep structures
- Immunosuppression in diabetes: altered chemotaxis and cell-wall abnormalities of polymorphonuclear cells
- Most mild infections: gram-positive cocci (S. aureus, streptococci)
- Severe/deep infections: polymicrobial - aerobic gram-positive cocci + gram-negative bacilli + anaerobes
- Pseudomonas is over-represented; empirical therapy for severe infections should cover it
- Bailey and Love's Short Practice of Surgery 28th Ed
Classification Systems
Wagner Classification (most widely used)
| Grade | Description |
|---|
| 0 | Skin at risk (no open lesion; callus, pre-ulcer) |
| I | Superficial ulcer (skin/subcutaneous tissue only) |
| II | Deep ulcer - exposed tendon, joint capsule |
| III | Deep ulcer with abscess or osteomyelitis |
| IV | Partial gangrene (forefoot/toe) |
| V | More extensive gangrene |
Ulcers that are both infected and ischemic are 90 times more likely to require amputation. The presence of an infected ulcer carries a 40-55% chance of some form of amputation. - Campbell's Operative Orthopaedics 15th Ed 2026
WIfI Classification (Society for Vascular Surgery - preferred for threatened limb)
A newer system grading three domains from 0 (none) to 3 (severe):
- W - Wound
- I - Ischemia
- fI - foot Infection
64 possible permutations predict: (1) risk of major amputation at 1 year, and (2) estimated benefit of revascularization. Advanced WIfI stage correlates with prolonged wound healing, decreased 1-year amputation-free survival, and benefit of revascularization in chronic limb-threatening ischemia. - Current Surgical Therapy 14e
University of Texas Classification
Adds infection and ischemia dimensions to depth grading. The etiology of DFU is characterized as:
- Neuropathic (pure neuropathy, good blood supply)
- Ischemic (PAD-driven, neurologically intact)
- Neuroischemic (combined - most common and most dangerous)
Clinical Assessment
History
- Duration of diabetes, glycemic control (HbA1c)
- Episodes of prior ulceration, prior amputations
- Symptoms of claudication or rest pain
- Impaired vision, renal disease, paresthesias/numbness
- Note: impaired sensation means patients often deny pain or history of trauma
Physical Examination (Box 91.1 from Campbell's)
Inspect shoes:
- Undersized shoes → pressure over bony prominences
- Abnormal wear pattern → structural/dynamic deformity
- Prominent seams or foreign bodies patient cannot feel → confirms neuropathy
Foot inspection:
- Atrophy of extensor digitorum brevis → motor neuropathy
- Claw/hammer toes, foot drop → motor neuropathy
- Corns and calluses → precursors to ulceration
- Arch and hindfoot alignment
Skin:
- Dry, fissured skin (autonomic neuropathy)
- Warmth and erythema (infection or Charcot)
- Dependent rubor (ischemia)
Neurologic:
- 10-g Semmes-Weinstein monofilament at 10 sites (or 4.5-g beneath both first metatarsal heads for quicker screening)
- Pinprick, temperature, vibration, proprioception
Vascular:
- Pedal pulse assessment (may be unreliable due to calcification)
- ABI / toe-brachial index
- Ankle and toe pressures
Wound Assessment
- Debride callus first to expose true wound dimensions
- Probe to bone with sterile cotton swab (positive "probe-to-bone" test = high PPV for osteomyelitis)
- Assess for depth, tunneling, undermining, exudate
- Three-view foot X-ray for all patients: foreign bodies, soft tissue gas, bone abnormalities, Charcot deformity, prior amputations
Investigations
| Test | Purpose |
|---|
| CBC, ESR, CRP | Baseline inflammation; may be normal/mildly elevated even in severe infection |
| HbA1c | Glycemic control; values >7% associated with complications |
| Blood glucose | Pre-op >200 mg/dL increases risk of nonunion, infection, wound breakdown |
| Plain radiograph | Osteomyelitis (may be normal early), gas, foreign body |
| MRI | Most sensitive for osteomyelitis and bone involvement |
| Probe-to-bone test | Strongly suggests osteomyelitis when positive + elevated markers + X-ray changes |
| ABI / toe pressures | Vascular status; healing prediction |
| Deep tissue cultures (surgical) | Gold standard; superficial swabs/sinus tract cultures are unreliable |
| Bone biopsy culture | For complex/extensive infection |
Superficial swabs and cultures from ulcers or sinus tracts are not reliable for identifying causative organisms in deep infection. - Bailey and Love's 28th Ed
Management
General Principles (the pillars)
- Glycemic control
- Off-loading / pressure relief
- Wound debridement
- Infection control and antibiotics
- Vascular assessment and revascularization
- Appropriate footwear
Off-loading
- Total contact cast (TCC): gold standard for neuropathic plantar ulcers
- Removable cast walkers, walking braces, custom therapeutic footwear
- Strict non-weight-bearing for moderate-to-severe infections
Debridement
- Sharp debridement of all hypertrophic callus and non-viable tissue
- Goal: convert chronic wound to acute wound capable of healing
- Saline irrigation (avoid hydrogen peroxide, betadine - damage viable tissue)
- In OR for deeper/infected wounds
- For osteomyelitis: surgical resection of infected bone preferred
Antibiotics (by severity)
| Severity | Regimen |
|---|
| Mild (gram-positive organisms) | TMP-SMX 800/160 mg bid, OR cephalexin 500 mg qid, OR clindamycin 300 mg qid (oral) |
| Moderate-to-severe | Piperacillin-tazobactam 3.375 g IV q8h + vancomycin 15 mg/kg IV q12h |
| Anaerobic component (abscess/devitalized tissue) | Add metronidazole |
- Culture-specific antibiotics preferred once results available
- Simple toe amputations: 2-week oral course
- Partial ray amputation/metatarsal resection: 4-6 week prolonged course
- Rosen's Emergency Medicine, Current Surgical Therapy 14e, Bailey and Love's 28th Ed
Wound Care Products
- Advanced dressings (hydrocolloid, alginate, foam, silver-containing)
- Negative pressure wound therapy (NPWT): evidence supports use for diabetic foot ulcers; meta-analysis (PMID 39241769) confirms effectiveness in promoting healing
- Biological/dermal substitutes (e.g., Integra) for complex wounds after debridement
Vascular Intervention
- Full vascular assessment mandatory in patients with absent pulses or non-healing wounds
- Angioplasty or bypass surgery to improve distal vascularity before or alongside foot surgery
- Hyperbaric oxygen therapy (HBO): for Wagner grade 3+ with inadequate perfusion; shown 54% healing vs. 25% with standard methods; indicated for osteomyelitis, gangrene, or open wound with inadequate perfusion not amenable to revascularization
Surgical Treatment by Wagner Grade
| Grade | Treatment |
|---|
| 0 | Serial exams, education, accommodative footwear |
| I | Clinic debridement + off-loading (TCC, walking brace, custom footwear) |
| II | Surgical debridement + culture-specific antibiotics + total contact casting |
| III | Surgical debridement or partial amputation + off-loading + antibiotics |
| IV/V | Local or larger amputation based on extent of infection |
Amputation
- Wound healing after amputation in diabetics is unreliable
- Excision must be adequate to remove all infected tissue; excess bone resected for tension-free closure
- If extensive peripheral neuropathy, below-knee amputation in area with better sensation may be preferable
- Up to one-third of patients with deep/limb-threatening infection eventually undergo amputation
Charcot Neuropathic Arthropathy (Charcot Foot)
A progressive, destructive arthropathy of the foot and ankle seen in patients with peripheral neuropathy. Triggered by trauma (often unnoticed) in a neuropathic, hyperemic foot:
- Acute phase: warm, swollen, erythematous foot; often mistaken for infection or DVT
- Chronic/collapsed phase: midfoot collapse ("rocker-bottom deformity"), bony prominences → ulceration risk
- MRI and bone scan for diagnosis; plain X-rays show fragmentation, subluxation, destruction
- Management: strict off-loading in TCC until acute inflammation subsides (can take 3-12 months); surgical reconstruction for unstable or deformity-causing cases
Prevention
- Daily foot inspection (patient + carer)
- Therapeutic footwear: adequate toe box, no prominent seams, custom insoles
- Regular foot care by podiatrist
- Glycemic control: lower HbA1c = less peripheral neuropathy and fewer ulcers
- Annual monofilament screening of all diabetic patients
- Education on risk factors, proper nail care, avoiding barefoot walking
- Multidisciplinary diabetic foot clinic: demonstrated to reduce LEA rates through early recognition and management
Key Points Summary
- The triad of neuropathy + ischemia + infection drives nearly all diabetic foot complications
- Sensory loss is the pivotal defect - it removes the protective "alarm" of pain
- Wagner classification guides treatment decisions; WIfI better predicts limb threat
- MRI is the most sensitive modality for osteomyelitis
- Superficial swabs are unreliable - use deep tissue/bone cultures
- Total contact casting is the gold standard for off-loading neuropathic ulcers
- Severe infections: broad-spectrum IV antibiotics (pip-tazo + vancomycin ± metronidazole)
- Vascular assessment is mandatory - revascularize before/alongside wound management when possible
- Multidisciplinary care reduces amputation rates
Sources:
- Campbell's Operative Orthopaedics 15th Ed 2026, Ch. 91
- Bailey and Love's Short Practice of Surgery 28th Ed, Ch. 43
- Current Surgical Therapy 14e, Diabetic Foot chapter
- Rosen's Emergency Medicine, Ch. 115 / 125
- Recent evidence: NPWT meta-analysis, 2024, PMID 39241769 | Advanced wound dressings meta-analysis, 2024, PMID 38864979